齐拉西酮与利培酮治疗精神分裂症的对照研究

Ziprasidone and Risperidone on Treatment of Schizophrenia

目的:比较齐拉西酮与利培酮治疗精神分裂症的疗效与不良反应。方法:112例符合CCMD-3精神分裂症患者随机分为两组每组各56例,分别给予齐拉西酮与利培酮治疗8周,采用阳性症状与阴性症状量表及不良反应症状量表评定疗效与副反应。结果:治疗8周后,齐拉西酮组显效率64.3%,有效率89.3%,利培酮组显效率58.9%,有效率87.5%,两组疗效比较差异无统计学意义(P>0.05)。齐拉西酮组总不良反应发生率33.9%,利培酮组总不良反应发生率48.2%,两组间差异无统计学意义(P>0.05)。结论:齐拉西酮与利培酮治疗精神分裂症的疗效相当,副反应差异无统计学意义。齐拉西酮治疗精神分裂症安全有效。

Objective ： To compare the efficacy and safety of Ziprasidone and Risperidone on treatment of schizophrenia. Method： One hundered and twelve patients with schizophrenia conformed to CCMD-3 were devided into two grougs ramdomly and treated with Ziprasidone or Risperidone for 8 weeks respectively. The Positive and Negative Syndrome Scale （PANSS） and Treatment Emetgent Side Effect Scale（TESS） were used to evaluate the efficacy and adverse effect respectively. Result： The significant efficacy rate of Ziprasidone was 64.3% and the efficacy rate was 89.3% after 8 weeks, while that was 58.9% and 87.5% in Risperidone group. There were no statistical difference between two grougs（P 〉0.05） . The incidence rate of adverse effect was 33.9% in Ziprasidone group and that was 48.2% in Risperidone group,it were without statistical difference between them （P 〉 0.05 ）. Conclusion： Ziprasidone is an effective and safe drug as Risperidone on the treatment of sihizophrenia. The incidence of adverse effect in two drugs have no statistical difference, Ziprasidone has good efficacy and safety in the treatment of schizophrenia.